BioCryst Pharmaceuticals, Inc.
NEWS
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.
There was a fair amount of clinical trial news last week. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
BioCryst Pharmaceuticals, Inc. announced on Thursday that the U.S. Food and Drug Administration (FDA) has approved ORLADEYO (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and young patients 12 years and older.
The end of November and beginning of December is marked by several PDUFA dates at the U.S. Food and Drug Administration (FDA). Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
JOBS
IN THE PRESS